Table 4.
DOACs versus VKAs for the treatment of VTE in patients with CKD
| Author | Database | CrCl, mL/min | N | Treatment arms | Age, years | Males, % | Recurrent VTE HR (95% CI) | Major bleeding HR (95% CI) |
|---|---|---|---|---|---|---|---|---|
| Agnelli et al. [112] | AMPLIFY | 30–50 | – | Apixaban vs. Warfarin (reference) | – | – | 0.93 (0.34–2.61)* | 0.52 (0.18–1.51)* |
| Goldhaber et al. [108] | RE-COVER | 30–50 | 237 | Dabigatran vs. Warfarin (reference) | – | – | – | 6.71 (3.34–13.48) |
| Bauersachs et al. [109] | EINSTEIN | 30–50 | 636 | Rivaroxaban | 79 (75–83) | 34 | 1.05 (0.44–2.47) | 0.23 (0.06–0.81) |
| Warfarin (reference) | 80 (75–84) | |||||||
| Verhamme et al. [111] | HOKUSAI-VTE | 30–50 | 268 | Edoxaban vs. Warfarin (reference) | 60±19 | 33 | 0.38 (0.15–0.98) | 0.66 (0.37–1.18)* |
| Wetmore et al. [113] | USRDS cohort | ESKD | 12,206 | Apixaban vs. Warfarin (reference) | 63±14 | 47 | 0.58 (0.43–0.77) | 0.78 (0.62–0.98) |
CI, confidence interval; CrCl, creatinine clearance; HR, hazard ratio; N, total number of patients; USRDS, US Renal Data System; VTE, venous thromboembolism.
*Relative risk reported.